![]() |
COVID-19 |
Free Subscription
1 Antiviral Res |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO COVID-19 is free of charge.
Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish
influenza virus replication.
Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286.
PubMed
Abstract available
Covid-19: Excluding doctors from vaccination programme puts patients at risk,
clinicians warn.
BMJ. 2025;391:r2141.
PubMed
Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research
Network.
Clin Infect Dis. 2025;81.
PubMed
Abstract available
Historical Advances in Clinical Trial Design and Expanding Representation as the
New Frontier for Innovation.
Clin Infect Dis. 2025;81.
PubMed
Abstract available
Vaccine and Treatment Evaluation Units: A Historical Perspective.
Clin Infect Dis. 2025;81.
PubMed
Abstract available
Comparative Effectiveness of Combination Therapy with Nirmatrelvir-Ritonavir and
Molnupiravir versus Monotherapy with Molnupiravir or Nirmatrelvir-Ritonavir in
Hospitalised COVID-19 Patients: A Target Trial Emulation Study.
Int J Infect Dis. 2025 Oct 3:108097. doi: 10.1016/j.ijid.2025.108097.
PubMed
Abstract available
Sex Differences in Adverse Event Reporting Rates Following COVID-19 Vaccination
in South Korea During the Pandemic.
Int J Infect Dis. 2025 Oct 6:108107. doi: 10.1016/j.ijid.2025.108107.
PubMed
Abstract available
The impact of the SARS-CoV-2 pandemic on the development of respiratory
infections caused by Aspergillus spp., Mucor spp., and Pneumocystis jirovecii
within the National Health System of Spain.
Int J Infect Dis. 2025 Oct 7:108101. doi: 10.1016/j.ijid.2025.108101.
PubMed
Abstract available
Etiology of Initial Treatment Failure in Non-immunosuppressed Adult Patients with
Community-acquired Pneumonia.
Int J Infect Dis. 2025 Oct 8:108110. doi: 10.1016/j.ijid.2025.108110.
PubMed
Abstract available
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2
recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months
follow-up result of an open-label, non-randomised extension of a phase 1/2 trial.
Int J Infect Dis. 2025 Oct 8:108108. doi: 10.1016/j.ijid.2025.108108.
PubMed
Abstract available
Prevalence and impact of SARS-CoV-2, influenza, respiratory syncytial virus (RSV)
infection and respiratory illness on UK healthcare workers during winter 2023/24
(September 2023 to March 2024): SIREN cohort study.
J Infect. 2025;91:106620.
PubMed
Abstract available
Proteomic and Phosphoproteomic Profiling of Kidney in Rhesus Macaques With
SARS-CoV-2 Infection.
J Med Virol. 2025;97:e70633.
PubMed
Abstract available
Longitudinal RSV Antibody Trends in Thai Children (0-8 Years): Association With
Seasonal Outbreak Patterns and Potential Immunity Debt During the COVID-19
Pandemic.
J Med Virol. 2025;97:e70629.
PubMed
Abstract available
Porcine hemagglutinating encephalomyelitis virus VW572 (not Gent/PS412 and
Labadie) uses the CD81 receptor and MVB-derived exosomal pathway for efficient
entry and spread in neuronal cells.
J Virol. 2025 Oct 8:e0117125. doi: 10.1128/jvi.01171.
PubMed
Abstract available
A structural roadmap for the formation of the coronavirus nsp3/nsp4 double
membrane vesicle pore and its implications for polyprotein processing and
replication/transcription.
J Virol. 2025 Oct 8:e0145725. doi: 10.1128/jvi.01457.
PubMed
Abstract available
A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification
of virus neutralization and antibody-dependent enhancement.
J Virol. 2025 Oct 8:e0099125. doi: 10.1128/jvi.00991.
PubMed
Abstract available
Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum
neutralizing antibodies against SARS-CoV-2 infection in rodents.
J Virol. 2025 Oct 10:e0031525. doi: 10.1128/jvi.00315.
PubMed
Abstract available
Through the Glass.
JAMA. 2025 Oct 9. doi: 10.1001/jama.2025.18165.
PubMed
COVID-19 Linked to Lasting and Underrecognized Smell Impairment.
JAMA. 2025 Oct 10. doi: 10.1001/jama.2025.17491.
PubMed
Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S.
Veterans.
N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
PubMed
Abstract available
Effects of exposure to pandemic-related stressors on anxiety and mood difficulty
during versus before the COVID-19 pandemic in United States Army soldiers and
veterans.
Nat Ment Health. 2025 Sep 29:10.1038/s44220-025-00505.
PubMed
Abstract available
Zhonghua Jie He He Hu Xi Za Zhi
[Intermittent hypoxia exposure in the rehabilitation of long COVID patients].
Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:961-964.
PubMed
Abstract available
Thank you for your interest in scientific medicine.